Synergy Pharmaceuticals Inc. Raises $200M Rule 144A Offering of 7.50% Convertible Senior Notes

synergy pharmaceuticals

Sichenzia Ross Friedman Ference LLP Represents Synergy Pharmaceuticals Inc. in $200M Rule 144A Offering of 7.50% Convertible Senior Notes

New York, NY – (Global Newswire, November 5, 2014) – New York based securities and corporate law firm Sichenzia Ross Friedman Ference LLP announced that it  represented Synergy Pharmaceuticals Inc. (NASDAQ: SGYP), a biopharmaceutical developer of drugs to treat gastrointestinal disorders and diseases, in a Rule 144A offering of $200 million of 7.50% Convertible Senior notes. The notes are convertibles into shares of Synergy Pharmaceutical’s common stock at a conversion price of approximately $3.11 per share.

The SRFF team was led by Partner Jeffrey J. Fessler.


Sichenzia Ross Ference LLP

Sichenzia Ross Ference LLP is a nationally recognized securities and corporate law firm that provides experienced representation in all matters involving the securities industry. Super Lawyers consistently recognizes our attorneys as among the highest rated securities lawyers in the nation. Our attorneys specialize in advising clients on private placements, initial (IPOs) and secondary public offerings, alternative public offerings, preparation of SEC filings and listings on major capital stock exchanges such as the NYSE (New York Stock Exchange), NASDAQ and OTC markets. In addition, our litigation and arbitration attorneys are highly skilled in representing clients from routine lawsuits to complex cases before the SEC, FINRA and other tribunals. We also represent clients in a range of residential and commercial real estate and trusts and estates matters.

Visit SRF's LinkedIn page
Sichenzia Ross Ference LLP
Click Here to Leave a Comment Below 0 comments

Leave a Reply: